Scroll for more



Maureen E. O’Connell
Director, Board of Directors


Ms. O’Connell became a Director for Sucampo in February 2013. She currently serves as the Executive Vice President, Chief Administrative Officer and Chief Financial Officer at Scholastic Inc., a position she has held since 2007, overseeing all aspects of the company’s operations. From 2005 to 2006, she was Executive Vice President and Chief Financial Officer at Affinion Group, Inc., a leading affinity direct marketer of membership, insurance and loyalty programs. Prior, Ms. O’Connell held a series of progressively more responsible positions, including President and Chief Operating Officer and Executive Vice President, Chief Financial and Administrative Officer at Gartner, Inc., a leading technology research and advisory firm.

Ms. O’Connell has also had additional senior management positions including Executive Vice President and Chief Financial Officer at Barnes & Noble, Chief Financial Officer and Vice President at Publishers Clearing House, Senior Vice President of Finance and Marketing Analysis at BMG Direct, and Chief Financial Officer and Senior Vice President at Primedia, Inc.

She earned a bachelor’s degree in accounting and economics from Stern School of Business Administration at New York University and is a Certified Public Accountant in the state of New York.

Contact Us
Tel: +1-301-961-3400

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.